ORION Biotech Catalyst Calendar
Menu

Free biotech catalyst calendar

Each date comes with the SEC sentence it came from. Open a line to see the sentence and how its wording has changed.Each date comes with its SEC sentence.

All stages · All sizes · All periods

Filters

Stage
Event type
Company size (public float)
Period

Optional; keeps the company’s stated period precision.

250 programs as of

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

Window ends in: Q4 2026

Grouped by the period end. The company's wording is retained in each row; no countdown is shown.

  1. GPCRStructure Therapeutics · AleniglipronTopline/data readout MatchedSEC ↗Watch

    Period the company stated: Q4 2026

    Q4 2026Details

    Structure Therapeutics Inc. (GPCR) · Aleniglipron

    Stage: Not stated

    Public float (as of ): $834M (SEC filing) · $500M–$2B

    Period the company stated: Q4 2026

    SWITCH Data

    SEC timing context:

    Q4 2026

    SEC Form 8-K · Filed: · Accession: 0001104659-26-105688 · Last checked: · Matched

    Earlier SEC statements (6)
    1. · “We anticipate data from the SWITCH trial in the fourth quarter of 2026.” · SEC filing
    2. · “data from body composition, type 2 diabetes/obesity and SWITCH clinical trials on track for Q4 2026” · SEC filing
    3. · “Structure plans to report new data from the following aleniglipron clinical trials in the second half of 2026” · SEC filing
    4. · “Data are expected in Q4 2026.” · SEC filing
    5. · “We anticipate data from the SWITCH study in the fourth quarter of 2026.” · SEC filing
    6. · “Data are expected in Q4 2026.” · SEC filing
  2. GPCRStructure Therapeutics · AleniglipronTopline/data readout MatchedSEC ↗Watch

    Period the company stated: Q4 2026

    Q4 2026Details

    Structure Therapeutics Inc. (GPCR) · Aleniglipron

    Stage: Not stated

    Public float (as of ): $834M (SEC filing) · $500M–$2B

    Period the company stated: Q4 2026

    Body Comp Data

    SEC timing context:

    Q4 2026

    SEC Form 8-K · Filed: · Accession: 0001104659-26-105688 · Last checked: · Matched

    Earlier SEC statements (8)
    1. · “We anticipate topline results from the body composition trial in the fourth quarter of 2026.” · SEC filing
    2. · “data from body composition, type 2 diabetes/obesity and SWITCH clinical trials on track for Q4 2026” · SEC filing
    3. · “Structure plans to report new data from the following aleniglipron clinical trials in the second half of 2026” · SEC filing
    4. · “Data are expected in Q4 2026.” · SEC filing
    5. · “We anticipate topline results from the body composition study in the fourth quarter of 2026.” · SEC filing
    6. · “Data from the Body Composition and Type 2 Diabetes / Obesity data expected in Q4 2026” · SEC filing
    7. · “The Company expects to report topline results from the ACCESS OLE and Body Composition studies in Q3 and Q4 2026, respectively.” · SEC filing
    8. · “Data are expected in Q4 2026.” · SEC filing
  3. GPCRStructure Therapeutics · AleniglipronTopline/data readout MatchedSEC ↗Watch

    Period the company stated: Q4 2026

    Q4 2026Details

    Structure Therapeutics Inc. (GPCR) · Aleniglipron

    Stage: Not stated

    Public float (as of ): $834M (SEC filing) · $500M–$2B

    Period the company stated: Q4 2026

    T2DM/Obesity Data

    SEC timing context:

    Q4 2026

    SEC Form 8-K · Filed: · Accession: 0001104659-26-105688 · Last checked: · Matched

    Earlier SEC statements (7)
    1. · “We anticipate data from the T2DM trial in the fourth quarter of 2026.” · SEC filing
    2. · “data from body composition, type 2 diabetes/obesity and SWITCH clinical trials on track for Q4 2026” · SEC filing
    3. · “Structure plans to report new data from the following aleniglipron clinical trials in the second half of 2026” · SEC filing
    4. · “Data are expected in Q4 2026.” · SEC filing
    5. · “We anticipate data from the T2DM study in the fourth quarter of 2026.” · SEC filing
    6. · “Data from the Body Composition and Type 2 Diabetes / Obesity data expected in Q4 2026” · SEC filing
    7. · “Data are expected in Q4 2026.” · SEC filing
  4. INCYIncyte · povorcitinibTopline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    are anticipated in the fourth quarter of 2026Details

    INCYTE CORP (INCY) · povorcitinib

    Stage: Phase 3SEC filing · “Phase 3”

    Public float (as of ): $11.2B (SEC filing) · Over $2B

    Period the company stated: fourth quarter of 2026

    Data from the Phase 3 studies (STOP-PN1 and STOP-PN2) evaluating povorcitinib in patients with moderate to severe prurigo nodularis (PN) are anticipated in the fourth quarter of 2026

    SEC Form EX-99.1 · Filed: · Accession: 0000879169-26-000053 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “Phase 3 data are anticipated in 2026” · SEC filing
  5. INCYIncyte · ruxolitinib creamTopline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    are anticipated in the fourth quarter of 2026Details

    INCYTE CORP (INCY) · ruxolitinib cream

    Stage: Phase 3SEC filing · “Phase 3”

    Public float (as of ): $11.2B (SEC filing) · Over $2B

    Period the company stated: fourth quarter of 2026

    Topline results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026

    SEC Form EX-99.1 · Filed: · Accession: 0000879169-26-000053 · Last checked: · Matched

    Earlier SEC statements (4)
    1. · “topline results anticipated in the fourth quarter of 2026” · SEC filing
    2. · “results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026” · SEC filing
    3. · “topline results anticipated in the fourth quarter of 2026” · SEC filing
    4. · “results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026” · SEC filing
  6. IOVAIovance Biotherapeutics · lifileucel (AMTAGVI)Topline/data readout MatchedSEC ↗Watch

    Period the company stated: 4Q26

    updates are expected in 4Q26.Details

    IOVANCE BIOTHERAPEUTICS, INC. (IOVA) · lifileucel (AMTAGVI)

    Stage: Not stated

    Public float (as of ): $534M (SEC filing) · $500M–$2B

    Period the company stated: 4Q26

    Enrollment is nearly complete in the pivotal cohorts and program updates are expected in 4Q26.

    SEC Form 8-K · Filed: · Accession: 0001104659-26-091619 · Last checked: · Matched

  7. JSPRJasper Therapeutics · KP-104 (vensobafusp alfa)Topline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    trial is expected in the fourth quarter of 2026.Details

    Jasper Therapeutics, Inc. (JSPR) · KP-104 (vensobafusp alfa)

    Stage: Phase 2SEC filing · “Phase 2”

    Public float (as of ): $74M (SEC filing) · Under $500M

    Period the company stated: fourth quarter of 2026

    KP-104 is currently being evaluated in a Phase 2 basket trial in rare renal indications and interim data from Stage 1 of the trial is expected in the fourth quarter of 2026.

    SEC Form 8-K · Filed: · Accession: 0001213900-26-090055 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “The Combined Company expects to report interim data from Stage 1 of the ongoing Phase 2 basket trial in rare renal indications in the fourth quarter of 2026, and updated data in the second quarter of 2027.” · SEC filing
  8. KYMRKymera Therapeutics · KT-579Topline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    with data expected in the fourth quarter of 2026Details

    Kymera Therapeutics, Inc. (KYMR) · KT-579

    Stage: Phase 1SEC filing · “Phase 1”

    Public float (as of ): $2.2B (SEC filing) · Over $2B

    Period the company stated: fourth quarter of 2026

    Phase 1 clinical trial in healthy volunteers , with data expected in the fourth quarter of 2026

    SEC Form EX-99.1 · Filed: · Accession: 0001193125-26-333834 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “data expected to be reported in the second half of 2026” · SEC filing
  9. LXRXLexicon Pharmaceuticals · sotagliflozinNDA/BLA submission MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    will occur in the fourth quarter of 2026 based on current estimated timing of dataDetails

    LEXICON PHARMACEUTICALS, INC. (LXRX) · sotagliflozin

    Stage: Not stated

    Public float (as of ): $170M (SEC filing) · Under $500M

    Period the company stated: fourth quarter of 2026

    support a resubmission of the company's New Drug Application (NDA), which Lexicon anticipates will occur in the fourth quarter of 2026 based on current estimated timing of data collection.

    SEC Form 8-K · Filed: · Accession: 0001062822-26-000112 · Last checked: · Matched

  10. MIRMMirum Pharmaceuticals · brelovitugTopline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    are expected in the fourth quarter of 2026Details

    Mirum Pharmaceuticals, Inc. (MIRM) · brelovitug

    Stage: Phase 3SEC filing · “Phase 3”

    Public float (as of ): $2.3B (SEC filing) · Over $2B

    Period the company stated: fourth quarter of 2026

    Topline results from the Phase 3 AZURE-4 study, the second of the two pivotal studies supporting the U.S. registration package, are expected in the fourth quarter of 2026

    SEC Form 8-K · Filed: · Accession: 0001759425-26-000049 · Last checked: · Matched

    Earlier SEC statements (3)
    1. · “Brelovitug AZURE-1 and AZURE-4 Phase 3 studies in chronic hepatitis delta virus (HDV) topline results expected in Q3 and Q4 2026, respectively.” · SEC filing
    2. · “Completed enrollment in brelovitug AZURE-1 and AZURE-4 Phase 3 studies in HDV; topline results expected in H2 2026.” · SEC filing
    3. · “AZURE-4 studies in HDV topline data expected H2 2026” · SEC filing
  11. OCULOcular Therapeutix · AXPAXLI (OTX-TKI)Topline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    of the SOL-R trial in the fourth quarter of 2026 to provide Week 52 safety data on subjectsDetails

    OCULAR THERAPEUTIX, INC (OCUL) · AXPAXLI (OTX-TKI)

    Stage: Not stated

    Public float (as of ): $1.6B (SEC filing) · $500M–$2B

    Period the company stated: fourth quarter of 2026

    we plan to conduct an interim safety analysis of the SOL-R trial in the fourth quarter of 2026 to provide Week 52 safety data on subjects dosed with AXPAXLI in the trial in support of our NDA for AXPAXLI for the treatment of wet AMD.

    SEC Form 10-Q · Filed: · Accession: 0001104659-26-089450 · Last checked: · Matched

  12. OCULOcular Therapeutix · AXPAXLI (OTX-TKI)NDA/BLA submission MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    of wet AMD during the fourth quarter of 2026.Details

    OCULAR THERAPEUTIX, INC (OCUL) · AXPAXLI (OTX-TKI)

    Stage: Not stated

    Public float (as of ): $1.6B (SEC filing) · $500M–$2B

    Period the company stated: fourth quarter of 2026

    we anticipate submitting a new drug application, or NDA, to the FDA for marketing approval of AXPAXLI for the treatment of wet AMD during the fourth quarter of 2026.

    SEC Form 10-Q · Filed: · Accession: 0001104659-26-089450 · Last checked: · Matched

  13. PHATPhathom Pharmaceuticals · vonoprazan (VOQUEZNA)Topline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    are expected during the fourth quarter of 2026.Details

    Phathom Pharmaceuticals, Inc. (PHAT) · vonoprazan (VOQUEZNA)

    Stage: Not stated

    Public float (as of ): $555M (SEC filing) · $500M–$2B

    Period the company stated: fourth quarter of 2026

    Topline results from the 12-week blinded treatment portion of the trial are expected during the fourth quarter of 2026.

    SEC Form 10-Q · Filed: · Accession: 0001193125-26-324867 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “Topline results are anticipated in the fourth quarter 2026.” · SEC filing
  14. PMVPPMV Pharmaceuticals · rezatapopt (PC14586)Topline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    medical conference in the fourth quarter of 2026, including the primary analysis data from theDetails

    PMV Pharmaceuticals, Inc. (PMVP) · rezatapopt (PC14586)

    Stage: Phase 2SEC filing · “Phase 2”

    Public float (as of ): $53M (SEC filing) · Under $500M

    Period the company stated: fourth quarter of 2026

    The Company plans to provide an update on all PYNNACLE Phase 2 pivotal trial cohorts at a medical conference in the fourth quarter of 2026, including the primary analysis data from the ovarian cancer cohort.

    ClinicalTrials.gov NCT04585750 · NCT stated in SEC filing

    SEC Form 8-K · Filed: · Accession: 0001193125-26-376723 · Last checked: · Matched

  15. PTCTPTC Therapeutics · ST-920 · Fabry diseaseNDA/BLA submission MatchedSEC ↗Watch

    Period the company stated: in Q4 2026

    expected to be completed in Q4 2026.Details

    PTC THERAPEUTICS, INC. (PTCT) · ST-920 · Fabry disease

    Stage: Not stated

    Public float (as of ): $3.3B (SEC filing) · Over $2B

    Period the company stated: in Q4 2026

    A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.

    SEC Form 8-K · Filed: · Accession: 0001070081-26-000023 · Last checked: · Matched

    Earlier SEC statements (3)
    1. · “a rolling biologics license application (“BLA”) submission to the U.S. Food and Drug Administration for accelerated approval of ST-920 is expected to be completed in the fourth quarter of 2026.” · SEC filing
    2. · “A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.” · SEC filing
    3. · “A rolling biologics license application (“BLA”) submission to FDA for accelerated approval of ST-920 is expected to be completed in the fourth quarter of 2026.” · SEC filing
  16. RAPPRapport Therapeutics · RAP-219 · drug-resistant FOSTopline/data readout MatchedSEC ↗Watch

    Period the company stated: the fourth quarter of 2026

    trial is expected in the fourth quarter of 2026.Details

    Rapport Therapeutics, Inc. (RAPP) · RAP-219 · drug-resistant FOS

    Stage: Not stated

    Public float (as of ): $275M (SEC filing) · Under $500M

    Period the company stated: the fourth quarter of 2026

    Data from the open-label trial is expected in the fourth quarter of 2026.

    SEC Form 10-Q · Filed: · Accession: 0001193125-26-333862 · Last checked: · Matched

    Earlier SEC statements (3)
    1. · “Data from the open-label trial is expected in the second half of 2026.” · SEC filing
    2. · “Data from the trial is expected to be released in the second half of 2026.” · SEC filing
    3. · “initial data from the OLE are expected in the second half of 2026.” · SEC filing
  17. RAREUltragenyx Pharmaceutical · UX701Topline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    stage are expected in the fourth quarter of 2026Details

    Ultragenyx Pharmaceutical Inc. (RARE) · UX701

    Stage: Not stated

    Public float (as of ): $3.4B (SEC filing) · Over $2B

    Period the company stated: fourth quarter of 2026

    Data from this stage are expected in the fourth quarter of 2026

    SEC Form EX-99.1 · Filed: · Accession: 0001193125-26-332802 · Last checked: · Matched

  18. RVMDRevolution Medicines · RAS(ON) inhibitor combinationsTopline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    data in CRC in the fourth quarter of 2026.Details

    Revolution Medicines, Inc. (RVMD) · RAS(ON) inhibitor combinations

    Stage: Not stated

    Public float (as of ): $6.7B (SEC filing) · Over $2B

    Period the company stated: fourth quarter of 2026

    We currently expect to provide updated combination data in CRC in the fourth quarter of 2026.

    SEC Form 10-Q · Filed: · Accession: 0001193125-26-335104 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “We currently expect to provide updated combination data in CRC in 2026.” · SEC filing
  19. SLSSELLAS Life Sciences Group · SLS009Topline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    data expected in the fourth quarter of 2026.Details

    SELLAS Life Sciences Group, Inc. (SLS) · SLS009

    Stage: Phase 2SEC filing · “Phase 2”

    Public float (as of ): $219M (SEC filing) · Under $500M

    Period the company stated: fourth quarter of 2026

    with topline data expected in the fourth quarter of 2026.

    ClinicalTrials.gov NCT04588922 · NCT stated in SEC filing

    SEC Form 8-K · Filed: · Accession: 0001390478-26-000013 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “The topline data are expected in Q4 2026.” · SEC filing
  20. SNDXSyndax Pharmaceuticals · axatilimabTopline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    patients with IPF in the fourth quarter of 2026Details

    Syndax Pharmaceuticals Inc (SNDX) · axatilimab

    Stage: Phase 2SEC filing · “Phase 2”

    Public float (as of ): $799M (SEC filing) · $500M–$2B

    Period the company stated: fourth quarter of 2026

    topline data from MAXPIRe, a Phase 2, 26-week randomized, double-blinded, placebo-controlled trial of axatilimab on top of standard of care in patients with IPF in the fourth quarter of 2026

    SEC Form 10-Q · Filed: · Accession: 0001193125-26-332750 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “topline data on track for the second half of 2026” · SEC filing
  21. SNDXSyndax Pharmaceuticals · revumenibTopline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    with revumenib in the fourth quarter of 2026Details

    Syndax Pharmaceuticals Inc (SNDX) · revumenib

    Stage: Not stated

    Public float (as of ): $799M (SEC filing) · $500M–$2B

    Period the company stated: fourth quarter of 2026

    safety and efficacy data from R/R NUP98r acute leukemia patients treated with revumenib in the fourth quarter of 2026

    SEC Form 10-Q · Filed: · Accession: 0001193125-26-332750 · Last checked: · Matched

  22. SPRBSpruce Biosciences · TA-ERTNDA/BLA submission MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    IIIB anticipated in the fourth quarter of 2026Details

    SPRUCE BIOSCIENCES, INC. (SPRB) · TA-ERT

    Stage: Not stated

    Public float (as of ): $2M (SEC filing) · Under $500M

    Period the company stated: fourth quarter of 2026

    BLA submission for TA-ERT for the treatment of MPS IIIB anticipated in the fourth quarter of 2026

    SEC Form 8-K · Filed: · Accession: 0001193125-26-345874 · Last checked: · Matched

    Earlier SEC statements (2)
    1. · “anticipated BLA submission in the fourth quarter of 2026.” · SEC filing
    2. · “To accommodate this requirement, the timing of the BLA submission for TA-ERT is anticipated in the fourth quarter of 2026.” · SEC filing
  23. SYRESpyre Therapeutics · SPY072Topline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    data are expected in the fourth quarter of 2026.Details

    Spyre Therapeutics, Inc. (SYRE) · SPY072

    Stage: Not stated

    Public float (as of ): $1.1B (SEC filing) · $500M–$2B

    Period the company stated: fourth quarter of 2026

    axSpA sub-study: Double-blind, placebo-controlled safety and efficacy study of a single dose level of SPY072 at Week 16 with open-label follow-up through Week 40. Topline proof-of-concept data are expected in the fourth quarter of 2026.

    SEC Form 8-K · Filed: · Accession: 0001636282-26-000098 · Last checked: · Matched

  24. SYRESpyre Therapeutics · SPY072Topline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    data are expected in the fourth quarter of 2026.Details

    Spyre Therapeutics, Inc. (SYRE) · SPY072

    Stage: Not stated

    Public float (as of ): $1.1B (SEC filing) · $500M–$2B

    Period the company stated: fourth quarter of 2026

    PsA sub-study: Double-blind, placebo-controlled safety and efficacy study of a single dose level of SPY072 at Week 16 with open-label follow-up through Week 40. Topline proof-of-concept data are expected in the fourth quarter of 2026.

    SEC Form 8-K · Filed: · Accession: 0001636282-26-000098 · Last checked: · Matched

  25. TNYATenaya Therapeutics · TN-201Topline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    clinical trial in the fourth quarter of 2026.Details

    Tenaya Therapeutics, Inc. (TNYA) · TN-201

    Stage: Not stated

    Public float (as of ): $63M (SEC filing) · Under $500M

    Period the company stated: fourth quarter of 2026

    Tenaya plans to report additional interim data from the MyPEAK-1 clinical trial in the fourth quarter of 2026.

    SEC Form 8-K · Filed: · Accession: 0001193125-26-335098 · Last checked: · Matched

    Earlier SEC statements (2)
    1. · “In the second half of 2026, one-year Cohort 2 data and two-year Cohort 1 data from MyPEAK-1 are anticipated.” · SEC filing
    2. · “In the second half of 2026, one-year Cohort 2 data and two-year Cohort 1 data from MyPEAK-1 are anticipated.” · SEC filing
  26. TNYATenaya Therapeutics · TN-401Topline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    clinical trial in the fourth quarter of 2026.Details

    Tenaya Therapeutics, Inc. (TNYA) · TN-401

    Stage: Not stated

    Public float (as of ): $63M (SEC filing) · Under $500M

    Period the company stated: fourth quarter of 2026

    Tenaya expects to report additional interim data from the RIDGE-1 clinical trial in the fourth quarter of 2026.

    SEC Form 8-K · Filed: · Accession: 0001193125-26-335098 · Last checked: · Matched

  27. VIRVir Biotechnology · elebsiran + tobevibartTopline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    trial are expected in the fourth quarter of 2026.Details

    Vir Biotechnology, Inc. (VIR) · elebsiran + tobevibart

    Stage: Phase 3SEC filing · “Phase 3”

    Public float (as of ): $689M (SEC filing) · $500M–$2B

    Period the company stated: fourth quarter of 2026

    Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.

    ClinicalTrials.gov NCT06903338 · NCT stated in SEC filing

    SEC Form 8-K · Filed: · Accession: 0001628280-26-053351 · Last checked: · Matched

    Earlier SEC statements (4)
    1. · “• Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.” · SEC filing
    2. · “• Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.” · SEC filing
    3. · “Topline results from ECLIPSE 1 are expected in the fourth quarter of 2026” · SEC filing
    4. · “Topline data from the ECLIPSE 1 trial are expected in the fourth quarter of 2026.” · SEC filing
  28. VYGRVoyager Therapeutics · VY7523Topline/data readout MatchedSEC ↗Watch

    Period the company stated: Q4 2026

    imaging efficacy data in Q4 2026 from the ongoing multiple ascending dose (MAD) clinicalDetails

    Voyager Therapeutics, Inc. (VYGR) · VY7523

    Stage: Not stated

    Public float (as of ): $144M (SEC filing) · Under $500M

    Period the company stated: Q4 2026

    Voyager expects tau positron emission tomography (PET) imaging efficacy data in Q4 2026 from the ongoing multiple ascending dose (MAD) clinical trial in participants with Alzheimer’s disease (AD).

    SEC Form 8-K · Filed: · Accession: 0001640266-26-000007 · Last checked: · Matched

    Earlier SEC statements (6)
    1. · “Voyager continues to expect tau positron emission tomography (PET) imaging efficacy data in H2 2026 from the ongoing multiple ascending dose (MAD) clinical trial in AD patients.” · SEC filing
    2. · “Enrollment in this MAD clinical trial was completed in the fourth quarter of 2025, and we expect initial tau positron emission tomography imaging efficacy data in the second half of 2026.” · SEC filing
    3. · “We expect initial tau positron emission tomography, or PET, imaging data in the second half of 2026.” · SEC filing
    4. · “VY7523 is currently in a Phase 1, multiple ascending dose, or MAD, clinical trial in early AD patients, from which we expect initial tau positron emission tomography, or PET, imaging data in the second half of 2026.” · SEC filing
    5. · “Initial tau PET imaging data are expected in the second half of 2026.” · SEC filing
    6. · “generate initial data for slowing the spread of pathological tau via tau positron emission tomography, or PET, imaging in the second half of 2026.” · SEC filing
  29. ZBIOZenas BioPharma · obexelimabTopline/data readout MatchedSEC ↗Watch

    Period the company stated: fourth quarter of 2026

    population results in the fourth quarter of 2026.Details

    Zenas BioPharma, Inc. (ZBIO) · obexelimab

    Stage: Phase 2SEC filing · “Phase 2; Phase 2”

    Public float (as of ): $259M (SEC filing) · Under $500M

    Period the company stated: fourth quarter of 2026

    Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026: Zenas anticipates reporting topline overall and biomarker population results in the fourth quarter of 2026.

    ClinicalTrials.gov NCT06559163 · NCT stated in SEC filing

    SEC Form 8-K · Filed: · Accession: 0001104659-26-095437 · Last checked: · Matched

    Earlier SEC statements (9)
    1. · “we expect to report topline results, including biomarker data, in the fourth quarter 2026.” · SEC filing
    2. · “In April 2026, we completed enrollment in the SunStone trial and expect to report topline results, including biomarker data, in the fourth quarter of 2026.” · SEC filing
    3. · “Enrollment completed in Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) and topline results expected in 4Q 2026” · SEC filing
    4. · “Zenas anticipates reporting topline overall and biomarker population results in the fourth quarter of 2026.” · SEC filing
    5. · “we expect to report topline results, including biomarker data, in the fourth quarter of 2026.” · SEC filing
    6. · “We expect to report data on the primary endpoint at 24 weeks and biomarker data in the fourth quarter of 2026.” · SEC filing
    7. · “we expect to report topline results, including biomarker data, in the fourth quarter 2026.” · SEC filing
    8. · “We expect to report topline results, including biomarker data, from the SunStone trial, including biomarker data, in the fourth quarter of 2026.” · SEC filing
    9. · “We expect to complete enrollment in the SunStone trial by year-end 2025 and to report topline results from the SunStone trial in mid-2026.” · SEC filing

Window ends in: Q1 2027

Grouped by the period end. The company's wording is retained in each row; no countdown is shown.

  1. CRBPCorbus Pharmaceuticals Holdings · CRB-701 + pembrolizumabTopline/data readout MatchedSEC ↗Watch

    Period the company stated: Q1 2027

    data in 1L OPSCC in Q1 2027Details

    Corbus Pharmaceuticals Holdings, Inc. (CRBP) · CRB-701 + pembrolizumab

    Stage: Not stated

    Public float (as of ): $67M (SEC filing) · Under $500M

    Period the company stated: Q1 2027

    CRB-701 + pembrolizumab data in 1L OPSCC in Q1 2027

    SEC Form 8-K · Filed: · Accession: 0001193125-26-389829 · Last checked: · Matched

    Earlier SEC statements (2)
    1. · “anticipated data readout of CRB-701 in 1L OPSCC in early 2027” · SEC filing
    2. · “HNSCC patients in Q4 2026.” · SEC filing
About this calendar
Calendar

FDA dates and trial readouts as each company stated them, with SEC original links. 250 programs as of . Free, with no sign-in. No forecasts, prices or signals.

Add to Google Calendar Apple Calendar The subscription follows the filters chosen here. No sign-up; ORION stores nothing about subscribers.

How this calendar is made
  • Entries are grouped by their retained period length: a date (with its count of days), a month (counted to its last day), then a quarter, half or year with no count. Period headings describe the window end; each row retains the company's exact wording. A date is the target action date the company stated.
  • Company size is the public float (market value of shares held by non-affiliates) on the company’s latest cover, with its reference date and SEC link. It does not decide which programs are listed.
  • Stage repeats the SEC filing or ClinicalTrials.gov registration wording. Without supporting wording, it is Not stated. Mixed phases retain their exact wording beside the source link.
  • Medicine research links use an NCT number stated in the SEC filing or company announcement, or a ClinicalTrials.gov match with sponsor, medicine and phase evidence. A registry match is labelled “matched by ORION (not stated in the filing)”.
  • Rows link to the program or company page. For a stated date, month, quarter, half or year, the period ends on its calendar end. Ambiguous qualifiers retain their wording without inferred endpoints.
  • Ambiguous periods and events without a date retain the literal wording in a separate section. No calendar date or countdown is created; these records are excluded from calendar subscriptions.
  • Active windows have no resolution filing held and end on or after today (UTC). A row with resolution evidence is shown in Results disclosed. Other rows move to Window ended after the stated period ends. Earlier wording and filing links remain available.
  • Event types distinguish trial data, enrollment completion, site activation and event-based analysis. Financial results and FDA meetings have their own filters. Audit status remains in the SEC wording. The type follows the SEC wording.
  • Displayed items need a true public-display field and a matching SEC quote and timing proof. Machine extraction does not add a founder review.
  • “Wording changed” opens the earlier sentences, each with its date and filing.
  • No forecast, price, score or signal. The calendar repeats what companies wrote.

Want an email when one of these changes? Get a free Watch.

All companies A–Z

A PDUFA date is the target date by which the FDA aims to decide on a drug or biologic application.A Form 10-K is a company’s annual report to the SEC, with audited financial statements.